Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing
Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240